Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Second chance: new combo aims to clear hepatitis c after relapse

NCT ID NCT07565948

Disease control Sponsor: Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a 12-week course of three antiviral drugs (sofosbuvir, velpatasvir, and voxilaprevir) in 200 adults with chronic hepatitis C whose virus returned after previous treatment. The main goal is to see if the virus becomes undetectable 12 weeks after therapy ends. Researchers will also monitor liver function and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sofosbuvir/Velpatasvir/Voxilaprevir (a combination of three antiviral drugs)
What this could lead to
If successful, this could provide a reliable retreatment option for hepatitis C patients whose virus came back after initial therapy.
What could go wrong
This is a mid-stage study with 200 participants, so results may not apply to everyone. Some patients may not respond or may experience side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients between the age of 18-75, who have confirmed chronic hepatitis C virus (HCV) infection and experienced virologic relapse after prior direct-acting antiviral (DAA) therapy, with detectable HCV RNA at enrollment, and who received a 12-week regimen of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) as salvage treatment.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years at the time of enrollment 2. Confirmed chronic hepatitis C virus (HCV) infection 3. Documented virologic relapse after prior direct-acting antiviral (DAA) therapy 4. Detectable HCV RNA at screening 5. Received or planned to receive a 12-week regimen of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) as salvage therapy 6. Willing and able to provide written informed consent Exclusion Criteria: 1. Pregnant or breastfeeding women 2. Participation in another interventional clinical study during the study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis C virus (HCV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis C virus (HCV)

Contacts and locations

Locations

  • Xiangya Hospital of Central South University

    Changsha, Hunan, 410000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.